A precision medicine approach to Alzheimer’s disease
Alzheon is developing ALZ-801, one of the few oral drug candidates in advanced stages of clinical testing in Alzheimer’s disease (AD). ALZ-801 has a favorable safety profile and the potential to slow the course of the disease in all patients with Alzheimer’s.
ALZ-801, a prodrug, builds upon a large dataset in AD patients treated with the active molecule, tramiprosate. We have created a Precision Medicine approach to accelerating ALZ-801 development: by combining information on genetic markers and new insights into the pathology of AD, we have identified patients who would be ideal subjects for the initial pivotal program and approval. This approach is utilizing a genetic marker, which makes patient identification easy, and increases the likelihood that these patients will have an earlier onset and more rapid progression of AD.